The goal of our research is to improve our understanding of the genetic basis of blood disorders known as myeloid malignancies, and to use this knowledge to improve therapies for patients with these disorders. Our efforts are focused on the identification and characterization of somatic mutations in hematologic malignancies using candidate gene, genome-wide, and functional approaches, with a specific interest in the role of JAK-STAT signaling in malignant transformation and in the effects of mutations in epigenetic modifiers in myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML). As a physician-scientist, I have a specific interest in translating this knowledge back to the clinic, in the preclinical and clinical evaluation of targeted therapies for leukemia patients, and in the development of clinically tractable genomic assays for patients with hematologic malignancies.
